These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 38457191)
21. Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: an analysis of survival and treatment toxicities. Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ Oral Oncol; 2015 Feb; 51(2):190-4. PubMed ID: 25434585 [TBL] [Abstract][Full Text] [Related]
22. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757 [TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051 [TBL] [Abstract][Full Text] [Related]
24. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial. Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073 [TBL] [Abstract][Full Text] [Related]
25. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma. Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467 [TBL] [Abstract][Full Text] [Related]
26. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056 [TBL] [Abstract][Full Text] [Related]
27. Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Cao CN; Luo JW; Gao L; Yi JL; Huang XD; Wang K; Zhang SP; Qu Y; Li SY; Xiao JP; Zhang Z; Xu GZ PLoS One; 2015; 10(3):e0119101. PubMed ID: 25747589 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma. Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698 [TBL] [Abstract][Full Text] [Related]
29. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion. Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113 [TBL] [Abstract][Full Text] [Related]
30. Comparison of intensity-modulated radiation therapy alone vs. intensity-modulated radiation therapy combined with chemotherapy in elderly nasopharyngeal carcinoma patients (aged >65 years). Mi JL; Meng YL; Wu HL; Cao YL; Zhang B; Pan YF; Zhou YY; Fan JF; Liao SF; Qin XL; Yao DC; Jiang W Strahlenther Onkol; 2020 Mar; 196(3):270-279. PubMed ID: 31748837 [TBL] [Abstract][Full Text] [Related]
31. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study. Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256 [TBL] [Abstract][Full Text] [Related]
32. Analysis of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Wu S; Quan R; Han L; Zhang H; Zhang B; Xu G; Li X Medicine (Baltimore); 2020 Jul; 99(30):e21325. PubMed ID: 32791728 [TBL] [Abstract][Full Text] [Related]
33. Definitive intensity-modulated radiation therapy for nasopharyngeal carcinoma: long-term outcome of a multicenter prospective study. Wang R; Wu F; Lu H; Wei B; Feng G; Li G; Liu M; Yan H; Zhu J; Zhang Y; Hu K J Cancer Res Clin Oncol; 2013 Jan; 139(1):139-45. PubMed ID: 22986812 [TBL] [Abstract][Full Text] [Related]
34. Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis. Saleh-Ebrahimi L; Zwicker F; Muenter MW; Bischof M; Lindel K; Debus J; Huber PE; Roeder F Radiat Oncol; 2013 Jan; 8():20. PubMed ID: 23347410 [TBL] [Abstract][Full Text] [Related]
35. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis. Luo Y; Qin Y; Lang J Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153 [TBL] [Abstract][Full Text] [Related]
36. Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma. Luo Y; Gao Y; Yang G; Lang J Biomed Res Int; 2016; 2016():4398498. PubMed ID: 27195286 [TBL] [Abstract][Full Text] [Related]
37. Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma. Ji X; Xie C; Hu D; Fan X; Zhou Y; Zheng Y PLoS One; 2013; 8(2):e56208. PubMed ID: 23441169 [TBL] [Abstract][Full Text] [Related]
38. Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study. Xu M; Zang J; Luo S; Wang J; Li X BMJ Open; 2021 Aug; 11(8):e045417. PubMed ID: 34341036 [TBL] [Abstract][Full Text] [Related]
39. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity-modulated radiotherapy. Chang H; Peng L; Tao YL; Chen C; Xiao WW; Hu YH; Gao YH Cancer Med; 2019 Jun; 8(6):2823-2831. PubMed ID: 31006996 [TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study. Chen W; Wang F; Yang Z; Zhang T; Shen M; Wang R; Kang M Ann Palliat Med; 2021 Nov; 10(11):11891-11900. PubMed ID: 34872313 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]